Medicare took its price-negotiation program into new territory this year, naming 15 more prescription drugs whose costs the government will bargain down for 2028 and, for the first time, reaching into the medicines patients receive in a doctor’s office rather than at the pharmacy counter. The federal government published the list on January 27, 2026, and the negotiated prices take effect January 1, 2028. The selected drugs accounted for roughly $27 billion in Medicare spending over a single year, which is why the move carries weight for older Americans who lean on brand-name treatments.
The third round finally reaches Part B drugs
Every prior round of Medicare price talks covered only Part D medicines, the pills and self-injected drugs that people pick up from a pharmacy. The latest selection from the Centers for Medicare and Medicaid Services breaks that pattern by adding drugs administered by a clinician, the kind billed under Part B and given as an infusion or injection during an appointment. Four of the newly named products fall primarily into that Part B category, a category that had been untouched by negotiation until now.
That distinction matters because Part B drugs are paid for differently than the ones a pharmacist hands over. A Medicare beneficiary typically owes 20 percent of the cost of a Part B drug after meeting the deductible, so the sticker price flows straight through to what the patient pays. When the underlying price of a physician-administered drug falls, the 20 percent share falls with it, which is a more direct line to a retiree’s wallet than many Part D changes deliver.
The four primarily Part B drugs named in the government’s third-cycle selection are Botox, used well beyond cosmetics for conditions such as chronic migraine and overactive bladder; Cimzia, an anti-inflammatory prescribed for rheumatoid arthritis and Crohn’s disease; Orencia, another rheumatoid arthritis treatment; and Entyvio, given for inflammatory bowel disease. These are not fringe medicines. They are delivered by infusion or injection in clinics and infusion centers to patients managing serious chronic illness, and their selection signals that the most expensive office-administered biologics are now within reach of negotiation rather than shielded from it.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
How the negotiation actually works and when the savings land
The program grew out of a 2022 law that, for the first time, let Medicare sit across the table from drug makers and set a maximum price rather than accept whatever the manufacturer charged. Each cycle targets a batch of high-spending drugs that have been on the market for years without generic or biosimilar competition. The manufacturers of all 15 drugs in this round agreed to take part, along with the maker of one older drug being renegotiated.
This cycle also marks the first time Medicare has reopened a price it already set, revisiting one drug from an earlier round for renegotiation. That ability to circle back matters because a negotiated price is not frozen for good; as clinical use or market conditions change, the government can return to the table on a drug it has already addressed. For patients, it means the roster of affected medicines and the prices attached to them are a moving target rather than a one-time event settled once and forgotten.
The calendar is deliberately slow, which is the part that trips up readers expecting an immediate discount. Negotiations run through 2026, the agreed prices are announced, and they do not reach patients until January 1, 2028. In the meantime the drugs stay at their current prices, so the headline is a preview of a scheduled change rather than a cut anyone will see at the counter this year. An explainer from the health-policy research group KFF tracks the cycles and the effective dates for each round.
The scale of this round is what sets it apart from a routine coverage tweak. According to the government’s fact sheet on the third cycle, the 15 selected drugs represented about 6 percent of combined Part B and Part D spending in the year measured, a concentration of dollars in a short list of widely used treatments. That is the arithmetic that lets a negotiation on a handful of products move real money across the whole program.
What older patients should watch between now and 2028
The immediate takeaway for a Medicare enrollee is that nothing on a pharmacy receipt changes because of this announcement in 2026 or 2027. The prices attached to these 15 drugs are set to arrive in 2028, and a patient currently taking one of them keeps paying today’s cost-sharing until then. Confusing a future negotiated price with a present-day discount is the easiest mistake to make with news like this.
The longer game is worth following for anyone on a brand-name infusion or a costly maintenance drug, because the program is designed to repeat. Each year brings a new batch of selected medicines, and the expansion into Part B means the treatments given in a clinic are now permanently in scope rather than shielded from negotiation. A retiree whose specialty drug is not on this list could see it named in a later cycle.
The open question is how much of the lower negotiated price a given patient ultimately keeps, since coverage rules, supplemental insurance, and out-of-pocket caps all sit between the government’s price and the final bill. The direction is clear enough: Medicare is steadily pulling more of its highest-cost drugs into a process that did not exist a few years ago, and the medicines administered in a doctor’s office are no longer exempt from it.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
